Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Abou-Alfa GK, Chan SL, Lin CC, Chiorean EG, Holcombe RF, Mulcahy MF, Carter WD, Patel K, Wilson WR, Melink TJ, Gutheil JC, Tsao CJ. Abou-Alfa GK, et al. Among authors: melink tj. Cancer Chemother Pharmacol. 2011 Aug;68(2):539-45. doi: 10.1007/s00280-011-1671-3. Epub 2011 May 19. Cancer Chemother Pharmacol. 2011. PMID: 21594722 Clinical Trial.
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
Konopleva M, Thall PF, Yi CA, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F, Jabbour E, Faderl S, Thomas D, Cortes J, Kadia T, Kornblau S, Daver N, Pemmaraju N, Nguyen HQ, Feliu J, Lu H, Wei C, Wilson WR, Melink TJ, Gutheil JC, Andreeff M, Estey EH, Kantarjian H. Konopleva M, et al. Among authors: melink tj. Haematologica. 2015 Jul;100(7):927-34. doi: 10.3324/haematol.2014.118455. Epub 2015 Feb 14. Haematologica. 2015. PMID: 25682597 Free PMC article. Clinical Trial.
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.
Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP, Wiernik PH, Carter WD, Gold DP, Melink TJ, Gutheil JC, Bender JF. Redfern CH, et al. Among authors: melink tj. J Clin Oncol. 2006 Jul 1;24(19):3107-12. doi: 10.1200/JCO.2005.04.4289. Epub 2006 Jun 5. J Clin Oncol. 2006. PMID: 16754937 Clinical Trial.
Phase I clinical investigation of amonafide.
Saez R, Craig JB, Kuhn JG, Weiss GR, Koeller J, Phillips J, Havlin K, Harman G, Hardy J, Melink TJ, et al. Saez R, et al. Among authors: melink tj. J Clin Oncol. 1989 Sep;7(9):1351-8. doi: 10.1200/JCO.1989.7.9.1351. J Clin Oncol. 1989. PMID: 2549205 Clinical Trial.
Immunomodulation of interleukin-2 by cyclophosphamide: a phase IB trial.
Abrams JS, Eiseman JL, Melink TJ, Sridhara R, Hiponia DJ, Bell MM, Belani CP, Adler WH, Aisner J. Abrams JS, et al. Among authors: melink tj. J Immunother Emphasis Tumor Immunol. 1993 Jul;14(1):56-64. doi: 10.1097/00002371-199307000-00008. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8399071 Clinical Trial.
17 results